Published in N Engl J Med on February 12, 2007
Study of Oral Rapamycin Plus Bare Metal Stents vs Drug Eltuting Stents (ORAR III) | NCT00552669
The Initial Double-Blind Drug-Eluting Stent vs Bare-Metal Stent Study. (RAVEL) | NCT00233805
Outcomes following coronary stenting in the era of bare-metal vs the era of drug-eluting stents. JAMA (2008) 2.47
Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. BMJ (2008) 2.09
Neutrophil-derived cathelicidin protects from neointimal hyperplasia. Sci Transl Med (2011) 1.84
Unanswered questions--drug-eluting stents and the risk of late thrombosis. N Engl J Med (2007) 1.70
Clinical effectiveness of coronary stents in elderly persons: results from 262,700 Medicare patients in the American College of Cardiology-National Cardiovascular Data Registry. J Am Coll Cardiol (2009) 1.55
Impact of drug-eluting stents among insulin-treated diabetic patients: a report from the National Heart, Lung, and Blood Institute Dynamic Registry. JACC Cardiovasc Interv (2008) 1.49
Two year follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. Clin Res Cardiol (2008) 1.18
Optical coherence tomography findings of very late stent thrombosis after drug-eluting stent implantation. Int J Cardiovasc Imaging (2011) 1.17
Very late stent thrombosis after primary percutaneous coronary intervention with bare-metal and drug-eluting stents for ST-segment elevation myocardial infarction: a 15-year single-center experience. JACC Cardiovasc Interv (2011) 1.16
Rapamycin regulates endothelial cell migration through regulation of the cyclin-dependent kinase inhibitor p27Kip1. J Biol Chem (2010) 1.14
Drug-eluting coronary stents--promise and uncertainty. N Engl J Med (2007) 0.99
Isopropylamine NONOate (IPA/NO) moderates neointimal hyperplasia following vascular injury. J Vasc Surg (2010) 0.97
Accounting for the mortality benefit of drug-eluting stents in percutaneous coronary intervention: a comparison of methods in a retrospective cohort study. BMC Med (2011) 0.95
Clinical outcomes in diabetic and non-diabetic patients with drug-eluting stents: results from the first phase of the prospective multicenter German DES.DE registry. Clin Res Cardiol (2010) 0.91
Long-term outcome after sirolimus-eluting stents versus bare metal stents in patients with diabetes mellitus: a patient-level meta-analysis of randomized trials. Clin Res Cardiol (2011) 0.89
'Miracle stents'--a future without restenosis. Mcgill J Med (2007) 0.89
New concepts in the design of drug-eluting coronary stents. Nat Rev Cardiol (2013) 0.87
Comparison of three age groups regarding safety and efficacy of drug-eluting stents (from the National Heart, Lung, and Blood Institute Dynamic Registry). Am J Cardiol (2011) 0.85
Biodegradable Metals for Cardiovascular Stents: from Clinical Concerns to Recent Zn-Alloys. Adv Healthc Mater (2016) 0.85
Drug-eluting stents in multivessel coronary artery disease: cost effectiveness and clinical outcomes. Adv Pharmacol Sci (2012) 0.83
Reporting of harm in randomized controlled trials evaluating stents for percutaneous coronary intervention. Trials (2009) 0.82
Impact of the introduction of drug eluting stents on clinical outcomes in patients undergoing percutaneous and surgical coronary artery revascularisation procedures in Western Australia. BMC Cardiovasc Disord (2013) 0.81
Stent thrombosis in real-world patients: a comparison of drug-eluting with bare metal stents. Neth Heart J (2007) 0.81
Combination coating of chitosan and anti-CD34 antibody applied on sirolimus-eluting stents can promote endothelialization while reducing neointimal formation. BMC Cardiovasc Disord (2012) 0.81
Acute coronary syndrome as a first presentation of systemic lupus erythematosus in a teenager: revascularization by hybrid coronary artery bypass graft surgery and percutaneous coronary intervention: case report. Pediatr Cardiol (2007) 0.81
Review of the treatment of acute coronary syndrome in elderly patients. Clin Interv Aging (2009) 0.81
Evidence-based cardiology in hemodialysis patients. J Am Soc Nephrol (2013) 0.81
Where does the Occluded Artery Trial leave the late open artery hypothesis? Heart (2007) 0.79
Evolution of percutaneous coronary intervention in patients with diabetes: a report from the National Heart, Lung, and Blood Institute-sponsored PTCA (1985-1986) and Dynamic (1997-2006) Registries. Diabetes Care (2010) 0.79
Compassionate use of a paclitaxel coated balloon in patients with refractory recurrent coronary in-stent restenosis. Clin Res Cardiol (2013) 0.79
Long-term outcome after drug-eluting stent implantation in comparison with bare metal stents: a single centre experience. Clin Res Cardiol (2010) 0.79
Two-year clinical outcome after carvedilol-loaded stent implantation in patients with coronary artery disease. Korean J Intern Med (2011) 0.78
Percutaneous coronary intervention for unprotected left main coronary artery stenosis. World J Cardiol (2010) 0.78
Evaluation of long-term clinical and health service outcomes following coronary artery revascularisation in Western Australia (WACARP): a population-based cohort study protocol. BMJ Open (2014) 0.78
Selective versus exclusive use of drug-eluting stents in treating multivessel coronary artery disease: a real-world cohort study. Tex Heart Inst J (2014) 0.78
Angiographic results of a Tacrolimus-eluting stent in acute coronary syndrome lesions. Clin Res Cardiol (2008) 0.77
Safety and efficacy of switching anticoagulation to aspirin three months after successful radiofrequency catheter ablation of atrial fibrillation. Yonsei Med J (2014) 0.77
Bioabsorbable stent quo vadis: a case for nano-theranostics. Theranostics (2014) 0.77
Diabetes mellitus: a prothrombotic state implications for outcomes after coronary revascularization. Vasc Health Risk Manag (2009) 0.77
Resolution of late sirolimus-eluting stent thrombosis after tirofiban treatment. Heart Vessels (2009) 0.76
Case scenario: a patient on dual antiplatelet therapy with an intracranial hemorrhage after percutaneous coronary intervention. Anesthesiology (2014) 0.76
A clinical evaluation of the ProNOVA XR polymer-free sirolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions (EURONOVA XR I study). Indian Heart J (2013) 0.76
Two-Year Follow-up of Sirolimus-Eluting Stents versus Paclitaxel-Eluting Stents in Acute Myocardial Infarction. Int J Angiol (2012) 0.76
Cobalt-chrome MULTI-LINK VISION-stent implantation in diabetics and complex lesions: results from the DaVinci-Registry. Clin Res Cardiol (2009) 0.76
Comparison of bare metal stent and paclitaxel-eluting stent using a novel rat aorta stent model. J Vet Sci (2011) 0.75
Controversies in the use & implementation of drug-eluting stent technology. Indian J Med Res (2012) 0.75
Real-world safety and effectiveness outcomes of a zotarolimus-eluting stent: final 3-year report of the RESOLUTE International study. J Interv Cardiol (2013) 0.75
Coronary Artery Revascularisation : Past, Present and Future. Med J Armed Forces India (2011) 0.75
Safety and efficacy of the Yukon Choice Flex sirolimus-eluting coronary stent in an all-comers population cohort. Indian Heart J (2014) 0.75
Role of insulin-like growth factor 1 in stent thrombosis under effective dual antiplatelet therapy. Postepy Kardiol Interwencyjnej (2014) 0.75
Long-term follow-up results in patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents: results from a single high-volume PCI centre. BMJ Open (2014) 0.75
Five-year clinical outcomes of drug-eluting stents according to on-label and off-label use. Korean J Intern Med (2016) 0.75
Perioperative management of patient with intracoronary stent presenting for noncardiac surgery. Ann Card Anaesth (2016) 0.75
A history of late and very late stent thrombosis is not associated with increased activation of the contact system, a case control study. Thromb J (2010) 0.75
Comparison of Clinical Outcomes in Patients Undergoing Coronary Intervention with Drug-Eluting Stents or Bare-Metal Stents: A Nationwide Population Study. Acta Cardiol Sin (2017) 0.75
Myocardial bridging is a potential risk factor of very late stent thrombosis of drug eluting stent. Med Sci Monit (2012) 0.75
A prospective study evaluating efficacy of polymer free Pronova XR stent in treatment of denovo coronary artery stenosis. Indian Heart J (2014) 0.75
Very Late Stent Thrombosis in a Drug-Eluting Stent due to Interruption of Anti-Platelet Agents in Patients With Acute Myocardial Infarction and Thrombocytosis. Korean Circ J (2011) 0.75
Randomized clinical trial comparing abluminal biodegradable polymer sirolimus-eluting stents with durable polymer sirolimus-eluting stents: Nine months angiographic and 5-year clinical outcomes. Medicine (Baltimore) (2016) 0.75
Repeat late instent-stenosis after an interval of four years in the same lesion after bare-metal and drug-eluting stent: a case report. Cases J (2009) 0.75
Cobalt-chromium stents in long lesions of large vessels: clinical and angiographic results. Tex Heart Inst J (2011) 0.75
Drug-eluting coronary stents: as safe as bare-metal stents, but optimized antiplatelet therapy may further improve clinical outcome. Eur J Clin Pharmacol (2007) 0.75
Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med (2010) 17.57
A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med (2002) 12.84
Protected carotid-artery stenting versus endarterectomy in high-risk patients. N Engl J Med (2004) 12.58
A prospective natural-history study of coronary atherosclerosis. N Engl J Med (2011) 10.66
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med (2014) 10.54
Clinical end points in coronary stent trials: a case for standardized definitions. Circulation (2007) 10.31
Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med (2013) 8.91
Guidelines on myocardial revascularization. Eur Heart J (2010) 8.85
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation (2003) 8.61
Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet (2007) 7.61
A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur Heart J (2003) 6.88
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J (2007) 6.51
Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation (2011) 6.36
Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet (2004) 5.94
Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med (2007) 5.77
Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med (2007) 5.37
Fluvastatin and perioperative events in patients undergoing vascular surgery. N Engl J Med (2009) 5.26
The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention (2005) 5.16
Percutaneous coronary intervention of functionally nonsignificant stenosis: 5-year follow-up of the DEFER Study. J Am Coll Cardiol (2007) 5.02
Long-term results of carotid stenting versus endarterectomy in high-risk patients. N Engl J Med (2008) 4.72
Are drug-eluting stents associated with a higher rate of late thrombosis than bare metal stents? Late stent thrombosis: a nuisance in both bare metal and drug-eluting stents. Circulation (2007) 4.71
High-resolution spiral computed tomography coronary angiography in patients referred for diagnostic conventional coronary angiography. Circulation (2005) 4.68
Soluble CD40 ligand in acute coronary syndromes. N Engl J Med (2003) 4.06
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation (2003) 3.94
Left ventricular dyssynchrony predicts response and prognosis after cardiac resynchronization therapy. J Am Coll Cardiol (2004) 3.87
Effect of posterolateral scar tissue on clinical and echocardiographic improvement after cardiac resynchronization therapy. Circulation (2006) 3.50
Guidelines on myocardial revascularization. Eur J Cardiothorac Surg (2010) 3.47
Intensive glucose regulation in hyperglycemic acute coronary syndrome: results of the randomized BIOMarker study to identify the acute risk of a coronary syndrome-2 (BIOMArCS-2) glucose trial. JAMA Intern Med (2013) 3.46
Standardized endpoint definitions for Transcatheter Aortic Valve Implantation clinical trials: a consensus report from the Valve Academic Research Consortium. J Am Coll Cardiol (2011) 3.37
Comparison of coronary bypass surgery with drug-eluting stenting for the treatment of left main and/or three-vessel disease: 3-year follow-up of the SYNTAX trial. Eur Heart J (2011) 3.29
A clinical randomized trial to evaluate the safety of a noninvasive approach in high-risk patients undergoing major vascular surgery: the DECREASE-V Pilot Study. J Am Coll Cardiol (2007) 3.28
Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med (2010) 3.27
Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur Heart J (2012) 3.19
Prognostic value of multislice computed tomography coronary angiography in patients with known or suspected coronary artery disease. J Am Coll Cardiol (2006) 3.16
Concern Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. Eur Heart J (2009) 3.14
A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet (2008) 3.12
Percutaneous left ventricular assist devices vs. intra-aortic balloon pump counterpulsation for treatment of cardiogenic shock: a meta-analysis of controlled trials. Eur Heart J (2009) 3.06
Coronary restenosis after sirolimus-eluting stent implantation: morphological description and mechanistic analysis from a consecutive series of cases. Circulation (2003) 3.01
Nonemergency PCI at hospitals with or without on-site cardiac surgery. N Engl J Med (2013) 2.98
Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol (2005) 2.90
Stent thrombosis. J Am Coll Cardiol (2010) 2.86
Left ventricular resynchronization is mandatory for response to cardiac resynchronization therapy: analysis in patients with echocardiographic evidence of left ventricular dyssynchrony at baseline. Circulation (2007) 2.85
Carotid artery stenting vs carotid endarterectomy: meta-analysis and diversity-adjusted trial sequential analysis of randomized trials. Arch Neurol (2010) 2.83
Decision-making in elderly patients with severe aortic stenosis: why are so many denied surgery? Eur Heart J (2005) 2.83
Comprehensive assessment of coronary artery stenoses: computed tomography coronary angiography versus conventional coronary angiography and correlation with fractional flow reserve in patients with stable angina. J Am Coll Cardiol (2008) 2.81
Diagnostic accuracy and clinical utility of noninvasive testing for coronary artery disease. Ann Intern Med (2010) 2.80
Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Am Coll Cardiol (2012) 2.78
Optimal left ventricular lead position predicts reverse remodeling and survival after cardiac resynchronization therapy. J Am Coll Cardiol (2008) 2.75
Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. JAMA (2005) 2.74
Effects of cardiac resynchronization therapy on overall mortality and mode of death: a meta-analysis of randomized controlled trials. Eur Heart J (2006) 2.74
Hospital delays in reperfusion for ST-elevation myocardial infarction: implications when selecting a reperfusion strategy. Circulation (2006) 2.72
Quality of life after PCI with drug-eluting stents or coronary-artery bypass surgery. N Engl J Med (2011) 2.65
Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA (2008) 2.59
Gender differences in the management and clinical outcome of stable angina. Circulation (2006) 2.59
Catheter-based intramyocardial injection of autologous skeletal myoblasts as a primary treatment of ischemic heart failure: clinical experience with six-month follow-up. J Am Coll Cardiol (2003) 2.56
Electropathological substrate of longstanding persistent atrial fibrillation in patients with structural heart disease: epicardial breakthrough. Circulation (2010) 2.56
Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial. Lancet (2011) 2.54
Should major vascular surgery be delayed because of preoperative cardiac testing in intermediate-risk patients receiving beta-blocker therapy with tight heart rate control? J Am Coll Cardiol (2006) 2.54
Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Circulation (2002) 2.53
Electropathological substrate of long-standing persistent atrial fibrillation in patients with structural heart disease: longitudinal dissociation. Circ Arrhythm Electrophysiol (2010) 2.51
Angiographic stent thrombosis after routine use of drug-eluting stents in ST-segment elevation myocardial infarction: the importance of thrombus burden. J Am Coll Cardiol (2007) 2.50
Incidence of recognized and unrecognized myocardial infarction in men and women aged 55 and older: the Rotterdam Study. Eur Heart J (2006) 2.48
Combined anatomical and clinical factors for the long-term risk stratification of patients undergoing percutaneous coronary intervention: the Logistic Clinical SYNTAX score. Eur Heart J (2012) 2.43
Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur Heart J (2005) 2.40
Feasibility of combined use of intravascular ultrasound radiofrequency data analysis and optical coherence tomography for detecting thin-cap fibroatheroma. Eur Heart J (2008) 2.36
The Carotid Revascularization Endarterectomy versus Stenting Trial: credentialing of interventionalists and final results of lead-in phase. J Stroke Cerebrovasc Dis (2010) 2.35
Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial. JACC Cardiovasc Interv (2013) 2.32
Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world": the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation (2003) 2.31
Relative merits of left ventricular dyssynchrony, left ventricular lead position, and myocardial scar to predict long-term survival of ischemic heart failure patients undergoing cardiac resynchronization therapy. Circulation (2010) 2.30
Assessment of the aortic annulus by multislice computed tomography, contrast aortography, and trans-thoracic echocardiography in patients referred for transcatheter aortic valve implantation. Catheter Cardiovasc Interv (2011) 2.30
The usefulness of brain natriuretic peptide in complex congenital heart disease: a systematic review. J Am Coll Cardiol (2012) 2.27
Diabetic and nondiabetic patients with left main and/or 3-vessel coronary artery disease: comparison of outcomes with cardiac surgery and paclitaxel-eluting stents. J Am Coll Cardiol (2010) 2.24
Bioresorbable scaffold: the advent of a new era in percutaneous coronary and peripheral revascularization? Circulation (2011) 2.20
2012 ESC STEMI guidelines and reperfusion therapy: Evidence base ignored, threatening optimal patient management. Heart (2013) 2.18
Feasibility of diastolic function assessment with cardiac CT: feasibility study in comparison with tissue Doppler imaging. JACC Cardiovasc Imaging (2011) 2.18
Differential clinical responses to everolimus-eluting and Paclitaxel-eluting coronary stents in patients with and without diabetes mellitus. Circulation (2011) 2.17
Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study. Circulation (2012) 2.17
N-terminal pro-B-type natriuretic peptide and its relationship with cardiac function in adults with congenital heart disease. J Am Coll Cardiol (2013) 2.15
Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. Lancet (2012) 2.14
Evaluation of plaque characteristics in acute coronary syndromes: non-invasive assessment with multi-slice computed tomography and invasive evaluation with intravascular ultrasound radiofrequency data analysis. Eur Heart J (2008) 2.13
Clinical outcomes for sirolimus-eluting stent implantation and vascular brachytherapy for the treatment of in-stent restenosis. Catheter Cardiovasc Interv (2004) 2.12